Welcome to

41th Symposium on Hormones and Cell Regulation

« GPCR dynamics for fine tuning of physiological processes »

Mont Ste Odile (France)
October 5th-8th, 2016

The registrations are open

Invited speakers : (alphabetical order)

Laura Bohn (Jupiter, USA), Michel Bouvier (Montreal, Canada), Jens Brüning (Cologne, Germany), Antony Davenport (Cambridge, UK), Martin Fussenegger (Zurich, Switzerland), Sebastien Granier (Montpellier, France), Lora Heisler (Aberdeen, UK), Stephane Laporte (Sherbrooke, Canada), Amadeu Llebaria (Barcelona, Spain), Martin Lohse (Wurzburg, Germany), Fional Marshall (Welwyn Garden City, UK), Bernard Mouillac (Montpellier, France), Colleen Niswender (Nashville, USA), Marc Parmentier (Brussels, Belgium), Philippe Rondard (Montpellier, France), Helgi Schiöth (Uppsala, Sweeden), Kristina Schoonjans (Lausanne, Switzerland), Thue Schwartz (Copenhagen, Denmark), Martine Smit (Amsterdam, The Netherlands), Dirk Trauner (Munich, Germany), Jürgen Wess (Bethesda, USA)

Themes covered :

          Structural dynamics and allosterism
          Biased ligand
          Novel ways to control and use GPCRs
          GPCRs as emerging therapeutic targets
          Metabolic regulation through GPCRs

Topics of the Symposium :

This meeting covers various aspects of the biology of G-protein-coupled receptors (GPCRs) and their signalling pathways. A special focus will be on new data and concepts concerning the structure and function of GPCRs, novel ways to control and to use this receptor class and on GPCRs in metabolism and other emerging fields relevant for pathophysiology and therapy.
GPCRs are the direct targets of a third of the pharmaceutical drugs presently on sale. They are involved in many clinical disorders including cardiovascular, endocrine, metabolic and neurological diseases, and they are still regarded as a prime source for the development of new drugs.
At this meeting, the most recent aspects of the research in the field will be presented by speakers of international reputation. Work of the last years has lead to new concepts in receptor regulation with direct impact on drug design. In parallel, a new pharmacology of GPCRs emerges from the concept of allostery and biased signalling applied to these receptors.   
GPCRs have also been recognized as promising tools for the engineering of cellular regulatory pathways. This involves novel techniques to control GPCR activity by redesigning ligands and/or receptor molecules, including new possibilities to control their activity with light. These approaches may eventually be applied to the field of synthetic biology and to the development of new diagnostic, preventive or therapeutic strategies.
Finally, various emerging areas in which novel GPCR functions have been discovered and will be exploited for drug development including the metabolic system will be covered by various speakers and new aspects of the research in these fields will be discussed.